Intake of polyunsaturated fat in relation to mortality among statin users and non-users in the Southern Community Cohort Study
Nutrition, Metabolism & Cardiovascular Diseases, 08/06/2015
Kiage JN, et al.
The results suggest potential benefits of PUFA consumption on mortality which are only apparent in the absence of statin therapy. It seems prudent to consider the potential benefit of PUFA consumption in the primary prevention of CVD among patients who are not candidates for statin therapy but are at increased risk for CVD and mortality.
Methods
- At baseline the mean±SD age was 52±9 years, 60% of participants were women, 54% had hypertension and 16% used statins.
- The authors observed modest inverse associations between n3–PUFA and n6–PUFA intake with mortality among non–statin users but not among statin users.
- In adjusted analyses, the HRs (95% CIs) for all–cause mortality (6,396 deaths over a median of 6.4 years) comparing the highest to the lowest quintile were 0.90 (0.82–1.00) for n3–PUFA and 0.80 (0.70–0.92) for n6–PUFA among non–statin users, whereas they were 1.06 (0.87–1.28) and 0.96 (0.78–1.19) for n3–PUFA and n6–PUFA, respectively, among statin users.
Results
- The results suggest potential benefits of PUFA consumption on mortality which are only apparent in the absence of statin therapy.
- It seems prudent to consider the potential benefit of PUFA consumption in the primary prevention of CVD among patients who are not candidates for statin therapy but are at increased risk for CVD and mortality.